How big is STAAR Surgical Co.?

As of Jun 18, STAAR Surgical Co. has a market capitalization of 823.62 million, with net sales of 279.13 million and a net profit of -71.08 million over the last four quarters. Shareholder's funds are 397.33 million, and total assets amount to 509.52 million.

As of Jun 18, STAAR Surgical Co. has a market capitalization of 823.62 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 279.13 million, while the sum of net profit for the same period is -71.08 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 397.33 million, and total assets amount to 509.52 million.

What does STAAR Surgical Co. do?

STAAR Surgical Co. designs and manufactures implantable lenses for the eye, operating in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of $43 million and a net loss of $54 million, with a market cap of $823.62 million.

Overview:<BR>STAAR Surgical Co. designs, develops, manufactures, and sells implantable lenses for the eye, operating in the Pharmaceuticals & Biotechnology industry with a micro-cap market classification.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 43 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -54 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 823.62 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.63 <BR>Return on Equity: -20.31% <BR>Price to Book: 2.35<BR><BR>Contact Details:<BR>Address: 25651 Atlantic Ocean Drive, LAKE FOREST CA: 92630 <BR>Tel: 1 626 3037902 <BR>Fax: 1 626 3598402 <BR>Website: http://www.staar.com

Should I buy, sell or hold STAAR Surgical Co.?

Who are in the management team of STAAR Surgical Co.?

As of March 2022, the management team of STAAR Surgical Co. includes Independent Chairman Louis Silverman, President and CEO Caren Mason, Directors Thomas Frinzi, Gilbert Kliman, Stephen Farrell, and John Moore. They oversee the company's strategic direction and operations.

As of March 2022, the management team of STAAR Surgical Co. includes the following individuals:<BR><BR>- Mr. Louis Silverman, who serves as the Independent Chairman of the Board.<BR>- Ms. Caren Mason, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. Thomas Frinzi, who is a Director.<BR>- Dr. Gilbert Kliman, who is also a Director.<BR>- Mr. Stephen Farrell, who serves as an Independent Director.<BR>- Mr. John Moore, who is an Independent Director.<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Is STAAR Surgical Co. overvalued or undervalued?

As of February 11, 2025, STAAR Surgical Co. is considered a risky investment due to its overvaluation and poor performance metrics, including a Price to Book Value of 2.53, an EV to Sales ratio of 2.39, a ROCE of -51.79%, and a 1-year return of -13.48% compared to the S&P 500's 17.14%.

As of 11 February 2025, the valuation grade for STAAR Surgical Co. has moved from fair to risky, indicating a deterioration in its investment appeal. The company appears to be overvalued, particularly given its negative performance metrics. Key ratios include a Price to Book Value of 2.53, an EV to Sales ratio of 2.39, and a troubling ROCE of -51.79%. In comparison to peers, iRhythm Technologies has a P/E of -111.60, while Integer Holdings Corp. is considered very expensive with a P/E of 41.17.<BR><BR>The stock has underperformed relative to the S&P 500 across multiple periods, with a 1-year return of -13.48% compared to the index's 17.14%. This trend reinforces the notion that STAAR Surgical Co. is not only facing valuation challenges but also struggles in delivering shareholder returns.

Is STAAR Surgical Co. technically bullish or bearish?

As of September 2, 2025, STAAR Surgical Co. has a mildly bullish trend, supported by a bullish MACD and daily moving average, but faces bearish signals from the weekly RSI and monthly KST, while underperforming the S&P 500 with a -13.48% return over the past year.

As of 2 September 2025, the technical trend for STAAR Surgical Co. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by a bullish MACD on the weekly timeframe and a bullish daily moving average. However, the weekly RSI is bearish, and the KST shows a bearish signal on the monthly timeframe. Additionally, the Bollinger Bands indicate a mildly bullish trend weekly but bearish monthly, while the Dow Theory reflects a mildly bearish stance on the weekly chart.<BR><BR>In terms of performance, STAAR Surgical has underperformed the S&P 500 over the past year, with a return of -13.48% compared to the S&P 500's 17.14%, and significantly underperformed over the 3-year and 5-year periods as well.